期刊文献+

2004-2009年宁夏流行性腮腺炎的流行特征 被引量:6

Epidemiological features of epidemic parotitis in Ningxia from 2004 to 2009
下载PDF
导出
摘要 目的分析近年来流行性腮腺炎流行特征,为防控流行性腮腺炎疫情的策略和措施提供科学依据。方法对国家疾病监测信息报告管理系统和突发公共卫生事件报告管理信息系统报告的流行性腮腺炎病例数据进行描述分析。结果 2004-2009年宁夏流行性腮腺炎报告发病率波动在35.45/10万-89.91/10万,2009年为最高年份,2006年石嘴山市报告发病率高达149.35/10万。该病多发于冬春季节,15岁以下儿童发病占报告病例总数的89.66%,2009年该年龄组报告发病率高达352.43/10万。流行性腮腺炎突发公共卫生事件均发生在学校,累计报告病例占报告病例总数的10.86%。结论宁夏流行性腮腺炎报告发病呈现上升趋势,局部地区发生暴发疫情;3-14岁的托幼儿童和中小学生是主要发病群体,仍然为2-5年一个流行高峰的自然流行规律。 Objective To find out the epidemic features of parotitis in Ningxia and provide basic information for the control and prevention.Methods Descriptive analysis was conducted on the data from national notifiable disease reported system(NNDRS).Results The incident rate of parotitis in Ningxia was between 35.45 and 89.91 per 100 000 form 2004 to 2009,the highest rate is in 2009 and the rate in Shizuishan reached 149.35 per 10000 in 2006.This disease focused easily on the seasons of winter and spring.The cases of children under the age of 15 years were 89.66% and the incident rate of these children was 352.43 per 100000 in 2009.The cases reported to public health emergencies system is 10.86% of the total cases reported for 6 years.Conclusion In recent years,the cases of parotitis in Ningxia is on the rise and outbreak in some district.The most cases are the children aged 3 to 14 years in school.
出处 《宁夏医学杂志》 CAS 2011年第3期236-237,I0001,共3页 Ningxia Medical Journal
关键词 流行性腮腺炎 流行特征 Epidemic parotitis Feature
  • 相关文献

参考文献10

二级参考文献18

  • 1胡家瑜,施燕,倪莹箐,刘红联,汤素文,王建国.麻疹 流行性腮腺炎 风疹联合疫苗2剂免疫的效果观察[J].中国计划免疫,2004,10(4):221-224. 被引量:93
  • 2林云,王金荣,曹家穗,王振海,何奔,吴志英,邱顺林,沈玉华,陆金星.不同厂家生产的冻干麻疹-风疹-腮腺炎三联减毒活疫苗免疫效果及安全性观察[J].中国预防医学杂志,2006,7(3):209-211. 被引量:15
  • 3吴志英,高慧娟,胡建锦,邱顺林,凌悦人.国产麻腮风减毒活疫苗免疫效果及安全性观察[J].浙江预防医学,2007,19(5):14-15. 被引量:8
  • 4PAHO. WHO Position on use of measles,mumpes and rubella (MMR) vaccine. EPI News, 2001, 23 (l): 5-10.
  • 5Markowitz LE,Katz SL. Measles vaccine.//Plotkin SA, Mortimer EA. Vaccines. Philadelphia: Saunders, 1994: 229-260.
  • 6Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events form dipheria / tetanus / pertussis and measles / mumps / rubella vaccines. Lancet, 1995, 345 (8949): 567- 569.
  • 7Lee CY. Immunogenicity / reactogenicity safety of 3 vaccine lots VS Merck & Co's MMR vaccine in healthy children aged 15 to 18 months(OL). Data on file.
  • 8Briss PA, Fehrs LJ, Parker RA, et al. Sustained transmission of mumps in a hIgGhly vaccinated population: assessment of primary vaccine failure and waning vaccine- induced imumunity [J] . Infect Dis, 1994,169: 77 - 82.
  • 9CDC. Measles, Mumps, and Rubella- Vaccine Use and Strategies for Elimination of Measles, Rubella, and Congenital Rubella Syndrome and Control of Mumps:Recommendations of the Advisory Committee on Immunization Practices (ACIP) [J] .MMWR, 1998, 47(No. RR- 8
  • 10Bottinger M. Immunity to rubella before and after vaccination against measles,mumps and rubella (MMR) at 12 years of age of the first generation offered MMR vaccination in Sweden at 18 months[J].Vaccine, 1995,13:1759 - 1762.

共引文献136

同被引文献36

引证文献6

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部